ICD-10 Coding for Chemotherapy-Induced Peripheral Neuropathy(G60.9, G60.9U, G62.0)
Learn about the ICD-10 coding for chemotherapy-induced peripheral neuropathy, including documentation requirements and common pitfalls.
Complete code families applicable to Chemotherapy-Induced Peripheral Neuropathy
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| G62.0 | Drug-induced polyneuropathy | Use when neuropathy is directly attributed to chemotherapy agents. |
|
| T45.1x5A | Adverse effect of antineoplastic and immunosuppressive drugs | Use as a secondary code to specify the adverse effect of chemotherapy. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutChemotherapy-Induced Peripheral Neuropathy
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Chemotherapy-Induced Peripheral Neuropathy.
Failing to document the specific chemotherapy agent.
Impact
Clinical: Inaccurate treatment records., Regulatory: Non-compliance with documentation standards., Financial: Potential reimbursement issues.
Mitigation
Use templates that prompt for agent specification., Regular training on documentation standards.
Using general neuropathy codes instead of G62.0
Impact
Reimbursement: May lead to incorrect reimbursement rates., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate healthcare data reporting.
Mitigation
Ensure documentation specifies drug-induced neuropathy.
Omitting the 7th character in T45.1x5_
Impact
Reimbursement: Affects risk adjustment and reimbursement accuracy., Compliance: Non-compliance with ICD-10 coding rules., Data Quality: Leads to data inaccuracies in treatment tracking.
Mitigation
Apply the correct 7th character based on treatment phase.
Documentation of Adverse Effects
Impact
Inadequate documentation of chemotherapy-induced neuropathy.
Mitigation
Implement comprehensive documentation templates.